These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

538 related articles for article (PubMed ID: 17705197)

  • 1. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
    Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
    Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy.
    Shayne M; Crawford J; Dale DC; Culakova E; Lyman GH;
    Breast Cancer Res Treat; 2006 Dec; 100(3):255-62. PubMed ID: 16705366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices.
    Lyman GH; Dale DC; Crawford J
    J Clin Oncol; 2003 Dec; 21(24):4524-31. PubMed ID: 14673039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy.
    Shayne M; Culakova E; Wolff D; Poniewierski MS; Dale DC; Crawford J; Lyman GH
    Cancer; 2009 Nov; 115(22):5319-28. PubMed ID: 19672945
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study.
    Lyman GH; Dale DC; Friedberg J; Crawford J; Fisher RI
    J Clin Oncol; 2004 Nov; 22(21):4302-11. PubMed ID: 15381684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of neutropenia on delivering planned chemotherapy for solid tumours.
    Khan S; Dhadda A; Fyfe D; Sundar S
    Eur J Cancer Care (Engl); 2008 Jan; 17(1):19-25. PubMed ID: 18181887
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer.
    Laskey RA; Poniewierski MS; Lopez MA; Hanna RK; Secord AA; Gehrig PA; Lyman GH; Havrilesky LJ
    Gynecol Oncol; 2012 Jun; 125(3):625-30. PubMed ID: 22426251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysis.
    Pettengell R; Schwenkglenks M; Bacon P; Lawrinson S; Duehrsen U
    Hematol Oncol; 2011 Dec; 29(4):177-84. PubMed ID: 21246591
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective evaluation of chemotherapy dose intensity and supportive care for early-stage breast cancer in a curative setting.
    Lyman GH; Dale DC; Tomita D; Whittaker S; Crawford J
    Breast Cancer Res Treat; 2013 Jun; 139(3):863-72. PubMed ID: 23771731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
    Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
    J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutropenic complications in advanced-stage non-Hodgkin's lymphoma: implications for the use of prophylactic recombinant human granulocyte-colony stimulating factor (G-CSF).
    Bobey N; Woodman RC
    Clin Invest Med; 1998 Apr; 21(2):63-70. PubMed ID: 9562926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Febrile neutropenia incidence and hematological toxicity with the FEC100-docetaxel regimen in the treatment of early-stage breast cancer.
    Cousin S; Le Rhun E; Mailliez A; Fournier C; Bonneterre J
    Bull Cancer; 2012; 99(7-8):75-80. PubMed ID: 22713627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Febrile neutropenia and related complications in breast cancer patients receiving pegfilgrastim primary prophylaxis versus current practice neutropaenia management: results from an integrated analysis.
    von Minckwitz G; Schwenkglenks M; Skacel T; Lyman GH; Pousa AL; Bacon P; Easton V; Aapro MS
    Eur J Cancer; 2009 Mar; 45(4):608-17. PubMed ID: 19110415
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model.
    Rivera E; Erder MH; Moore TD; Shiftan TL; Knight CA; Fridman M; Brannan C; Danel-Moore L; Hortobagyi GN;
    Cancer; 2003 Jul; 98(2):222-8. PubMed ID: 12872339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.
    Balducci L; Al-Halawani H; Charu V; Tam J; Shahin S; Dreiling L; Ershler WB
    Oncologist; 2007 Dec; 12(12):1416-24. PubMed ID: 18165618
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of febrile neutropenia and neutropenic infections in elderly patients receiving anthracycline-based chemotherapy for breast cancer without primary prophylaxis with colony-stimulating factors.
    Minisini A; Spazzapan S; Crivellari D; Aapro M; Biganzoli L
    Crit Rev Oncol Hematol; 2005 Feb; 53(2):125-31. PubMed ID: 15661563
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice.
    Weycker D; Barron R; Edelsberg J; Kartashov A; Lyman GH
    Breast Cancer Res Treat; 2012 May; 133(1):301-10. PubMed ID: 22270932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
    Lyman GH; Delgado DJ
    Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors.
    Pentheroudakis G; Fountzilas G; Kalofonos HP; Golfinopoulos V; Aravantinos G; Bafaloukos D; Papakostas P; Pectasides D; Christodoulou C; Syrigos K; Economopoulos T; Pavlidis N;
    Crit Rev Oncol Hematol; 2008 Jun; 66(3):237-47. PubMed ID: 18243010
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.